Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta.

Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E.

Pharmacogenet Genomics. 2006 Jan;16(1):43-50.

PMID:
16344721
2.

Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption.

Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E.

Carcinogenesis. 2005 Feb;26(2):449-57. Epub 2004 Nov 18.

PMID:
15550453
3.

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.

Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chang-Claude J, Chanock SJ, Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS, Giovannucci EL, Gong J, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M, Le Marchand L, Newcomb PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A, Schoen RE, Schumacher FR, Seminara D, Slattery ML, Thibodeau SN, Thomas F, Thornquist M, Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT; CCFR; GECCO.

JAMA. 2015 Mar 17;313(11):1133-42. doi: 10.1001/jama.2015.1815.

4.

C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.

Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM.

Pharmacogenet Genomics. 2009 Feb;19(2):113-20. doi: 10.1097/FPC.0b013e32831bd976.

5.

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.

McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, Forman D, Roland Wolf C, Barrett JH; Colorectal Cancer Study Group.

Pharmacogenet Genomics. 2005 Oct;15(10):713-21.

PMID:
16141797
6.

PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.

Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3020.

7.

Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.

Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA.

J Natl Cancer Inst. 2009 Feb 18;101(4):267-76. doi: 10.1093/jnci/djn484. Epub 2009 Feb 10.

8.

Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?

Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J.

Pharmacogenet Genomics. 2007 Aug;17(8):639-45.

PMID:
17622940
9.

Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.

Barry EL, Mott LA, Sandler RS, Ahnen DJ, Baron JA.

Cancer Prev Res (Phila). 2011 Dec;4(12):2072-82. doi: 10.1158/1940-6207.CAPR-11-0300. Epub 2011 Sep 19.

10.

Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway.

Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):538-45.

11.
12.

Inflammation-related gene polymorphisms and colorectal adenoma.

Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1126-31.

13.

A meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancer.

Nagao M, Sato Y, Yamauchi A.

PLoS One. 2013 Aug 13;8(8):e71126. doi: 10.1371/journal.pone.0071126. eCollection 2013.

14.

Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Kleinstein SE, Heath L, Makar KW, Poole EM, Seufert BL, Slattery ML, Xiao L, Duggan DJ, Hsu L, Curtin K, Koepl L, Muehling J, Taverna D, Caan BJ, Carlson CS, Potter JD, Ulrich CM.

Genes Chromosomes Cancer. 2013 May;52(5):437-49. doi: 10.1002/gcc.22042. Epub 2013 Feb 12.

15.

Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.

Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY, Hayes RB.

Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42.

16.

Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.

Poole EM, Hsu L, Xiao L, Kulmacz RJ, Carlson CS, Rabinovitch PS, Makar KW, Potter JD, Ulrich CM.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):547-57. doi: 10.1158/1055-9965.EPI-09-0869. Epub 2010 Jan 19.

17.

Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial.

Sansbury LB, Bergen AW, Wanke KL, Yu B, Caporaso NE, Chatterjee N, Ratnasinghe L, Schatzkin A, Lehman TA, Kalidindi A, Modali R, Lanza E.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):494-501.

18.

A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.

Edwards TL, Shrubsole MJ, Cai Q, Li G, Dai Q, Rex DK, Ulbright TM, Fu Z, Murff HJ, Smalley W, Ness R, Zheng W.

Cancer Prev Res (Phila). 2012 Jun;5(6):855-63. doi: 10.1158/1940-6207.CAPR-11-0459. Epub 2012 May 2.

19.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

20.

Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use.

Chia VM, Newcomb PA, Bigler J, Morimoto LM, Thibodeau SN, Potter JD.

Cancer Res. 2006 Jul 1;66(13):6877-83.

Supplemental Content

Support Center